公开(公告)号：US20110319394A1

公开(公告)日：2011-12-29

申请号：US13166212

申请日：2011-06-22

申请人： Takahiko TANIGUCHI ,  Masato YOSHIKAWA ,  Kasei MIURA ,  Tomoaki HASUI ,  Eiji HONDA ,  Keisuke IMAMURA ,  Makoto KAMATA ,  Haruhi KAMISAKI ,  John F. QUINN ,  Joseph RAKER ,  Fatoumata CAMARA ,  Yi WANG

发明人： Takahiko TANIGUCHI ,  Masato YOSHIKAWA ,  Kasei MIURA ,  Tomoaki HASUI ,  Eiji HONDA ,  Keisuke IMAMURA ,  Makoto KAMATA ,  Haruhi KAMISAKI ,  John F. QUINN ,  Joseph RAKER ,  Fatoumata CAMARA ,  Yi WANG

IPC分类号： A61K31/437 ,  C07D498/04 ,  A61P25/18 ,  C07D487/14 ,  A61K31/522 ,  A61K31/551 ,  C07D471/04 ,  C07D473/00

CPC分类号： A61K31/4353 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/551 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04 ,  C07D471/14 ,  C07D473/00 ,  C07D473/28 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04 ,  C07D498/08 ,  C07D519/00 ,  C07F7/10

摘要： The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia. The compound is represented by the formula (I): wherein the symbols are defined in the specification.

摘要翻译： 本发明提供具有PDE抑制作用的化合物，其可用作预防或治疗精神分裂症的药剂。 化合物由式（I）表示：其中符号在说明书中定义。

公开(公告)号：US20130023499A1

公开(公告)日：2013-01-24

申请号：US13343624

申请日：2012-01-04

申请人： Scott A. MITCHELL ,  Kevin S. CURRIE ,  Peter A. BLOMGREN ,  David M. ARMISTEAD ,  Joseph RAKER

发明人： Scott A. MITCHELL ,  Kevin S. CURRIE ,  Peter A. BLOMGREN ,  David M. ARMISTEAD ,  Joseph RAKER

IPC分类号： A61K31/4985 ,  A61K31/625 ,  A61K31/5377 ,  A61K31/551 ,  A61K31/501 ,  A61P37/06 ,  A61P29/00 ,  A61P37/08 ,  A61P35/00 ,  A61P35/02 ,  A61P11/06 ,  A61P11/00 ,  A61P25/00 ,  A61K31/538 ,  C12N5/071 ,  C12N5/0781 ,  G01N33/573 ,  C07D487/04

CPC分类号： C07D487/04

摘要： Certain chemical entities chosen from compounds represented by Formula I and pharmaceutically acceptable salts and mixtures thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer (e.g., B-cell lymphoma and leukemia), autoimmune diseases, inflammatory diseases, acute inflammatory reactions, and allergic disorders. Methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for determining the presence or absence of Syk kinase in a sample.